Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jan-Feb;49(1):124-126.
doi: 10.4103/0253-7613.201020.

Levetiracetam-induced leukocytoclastic vasculitis

Affiliations
Case Reports

Levetiracetam-induced leukocytoclastic vasculitis

Mrinal Gupta. Indian J Pharmacol. 2017 Jan-Feb.

Abstract

Drug-induced leukocytoclastic vasculitis is a small-vessel vasculitis that most commonly manifests with palpable purpuric lesions on gravity-dependent areas. Vasculitis occurs within weeks after initial administration of medication and demonstrates clearance upon withdrawal of medication. Levetiracetam, a pyrrolidone derivative, is used as an adjunctive therapy in patients with refractory focal epilepsy, myoclonic epilepsy, and primary generalized tonic-clonic seizures. We present a case of a 14-year-old female, who developed cutaneous small-vessel vasculitis within 8 days of initiation of levetiracetam. Vasculitis was successfully managed by discontinuation of medication and systemic corticosteroids. This adverse reaction, to the best of our knowledge, has not been previously reported in literature.

Keywords: Cutaneous small-vessel vasculitis; drug-induced leukocytoclastic vasculitis; immune complex; levetiracetam.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Palpable purpura and necrotic ulcers over lower extremities
Figure 2
Figure 2
Histopathological examination showing red blood cell extravasation, infiltration of neutrophils and eosinophils and fibrinoid necrosis (H and E, ×40) in the dermis

References

    1. Merkel PA. Drug-induced vasculitis. Rheum Dis Clin North Am. 2001;27:849–62. - PubMed
    1. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48:311–40. - PubMed
    1. Litt JZ. Drug Eruption Reference Manual. 12th ed. London: Taylor and Francis; 2006. pp. 655–6.
    1. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–32. - PubMed
    1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. - PubMed

Publication types

MeSH terms

Supplementary concepts